GOODMAN JESSE
SEC insider (Form 3/4/5 filer). CIK 0001756929. Director at Intellia Therapeutics, Inc. (NTLA) and 1 other issuer. 6 reported Form 4/5 transactions since Sep 2024; latest on Jun 9, 2026. Located in CAMBRIDGE, MA.
Companies GOODMAN JESSE has filed insider reports for
- Intellia Therapeutics, Inc. (NTLA): Director
- BiomX Inc. (PHGE): Director
GOODMAN JESSE
CIK: 0001756929
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jun 9, 2026NTLA
Intellia Therapeutics, Inc.
AwardDirect9.2K shares- - Jul 1, 2025NTLA
Intellia Therapeutics, Inc.
SaleDirect1.5K shares at avg. $9.23$14K - Jun 30, 2025NTLA
Intellia Therapeutics, Inc.
SaleDirect1.5K shares at avg. $9.56$15K - Jun 11, 2025NTLA
Intellia Therapeutics, Inc.
AwardDirect8K shares- - Apr 14, 2025PHGE
BiomX Inc.
AwardDirectCommon Stock Options - right to Buy
17.6K shares- - Apr 14, 2025PHGE
BiomX Inc.
AwardDirectCommon Stock Options - right to Buy
17.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 9, 2026 |  NTLA Intellia Therapeutics, Inc. | Award | 9,200 | - | $0 | Direct |
| Jul 1, 2025 | NTLA Intellia Therapeutics, Inc. | Sale | 1,547 | $9.23 | $14,279 | Direct |
| Jun 30, 2025 | NTLA Intellia Therapeutics, Inc. | Sale | 1,547 | $9.56 | $14,789 | Direct |
| Jun 11, 2025 | NTLA Intellia Therapeutics, Inc. | Award | 8,000 | - | - | Direct |
| Apr 14, 2025 |  PHGE BiomX Inc. | Award Common Stock Options - right to Buy | 17,600 | - | - | Direct |
| Apr 14, 2025 | PHGE BiomX Inc. | Award Common Stock Options - right to Buy | 17,600 | - | - | Direct |
1-6 of 6 transactions